Trader consensus on Polymarket prices a 0% implied probability for Hims & Hers Health (HIMS) to beat Q1 2026 earnings consensus of $0.04 per share and approximately $617 million in revenue, reflecting near-certain expectations of a miss driven by the company's February guidance of $600–625 million in sales—below initial Street estimates—due to a $65 million headwind from regulatory restrictions on compounded GLP-1 weight-loss drugs. Recent 23% downward revisions to EPS estimates over the past 30 days underscore margin pressures amid subscriber growth slowdowns in the core telehealth segment. Tail risks include upside surprises from cost efficiencies or higher-end revenue realization, though resolution after today's post-market release limits volatility windows.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于$12,658 交易量
$12,658 交易量
2026-05-11
$12,658 交易量
$12,658 交易量
2026-05-11
As of market creation, Hims & Hers Health is estimated to release earnings on May 11, 2026. The Street consensus estimate for Hims & Hers Health's GAAP EPS for the relevant quarter is $0.03 as of market creation. This market will resolve to "Yes" if Hims & Hers Health reports GAAP EPS greater than $0.03 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents.
If Hims & Hers Health releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Trader consensus on Polymarket prices a 0% implied probability for Hims & Hers Health (HIMS) to beat Q1 2026 earnings consensus of $0.04 per share and approximately $617 million in revenue, reflecting near-certain expectations of a miss driven by the company's February guidance of $600–625 million in sales—below initial Street estimates—due to a $65 million headwind from regulatory restrictions on compounded GLP-1 weight-loss drugs. Recent 23% downward revisions to EPS estimates over the past 30 days underscore margin pressures amid subscriber growth slowdowns in the core telehealth segment. Tail risks include upside surprises from cost efficiencies or higher-end revenue realization, though resolution after today's post-market release limits volatility windows.
As of market creation, Hims & Hers Health is estimated to release earnings on May 11, 2026. The Street consensus estimate for Hims & Hers Health's GAAP EPS for the relevant quarter is $0.03 as of market creation. This market will resolve to "Yes" if Hims & Hers Health reports GAAP EPS greater than $0.03 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents.
If Hims & Hers Health releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
If Hims & Hers Health releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
市场开放时间： Apr 29, 2026, 4:20 PM ET
交易量
$12,658结束日期
2026-05-11市场开放时间
Apr 29, 2026, 4:20 PM ETResolver
0x65070BE91...已提议结果: No
无争议
最终结果: No
As of market creation, Hims & Hers Health is estimated to release earnings on May 11, 2026. The Street consensus estimate for Hims & Hers Health's GAAP EPS for the relevant quarter is $0.03 as of market creation. This market will resolve to "Yes" if Hims & Hers Health reports GAAP EPS greater than $0.03 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents.
If Hims & Hers Health releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Trader consensus on Polymarket prices a 0% implied probability for Hims & Hers Health (HIMS) to beat Q1 2026 earnings consensus of $0.04 per share and approximately $617 million in revenue, reflecting near-certain expectations of a miss driven by the company's February guidance of $600–625 million in sales—below initial Street estimates—due to a $65 million headwind from regulatory restrictions on compounded GLP-1 weight-loss drugs. Recent 23% downward revisions to EPS estimates over the past 30 days underscore margin pressures amid subscriber growth slowdowns in the core telehealth segment. Tail risks include upside surprises from cost efficiencies or higher-end revenue realization, though resolution after today's post-market release limits volatility windows.
As of market creation, Hims & Hers Health is estimated to release earnings on May 11, 2026. The Street consensus estimate for Hims & Hers Health's GAAP EPS for the relevant quarter is $0.03 as of market creation. This market will resolve to "Yes" if Hims & Hers Health reports GAAP EPS greater than $0.03 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents.
If Hims & Hers Health releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
If Hims & Hers Health releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
交易量
$12,658结束日期
2026-05-11市场开放时间
Apr 29, 2026, 4:20 PM ETResolver
0x65070BE91...已提议结果: No
无争议
最终结果: No
Trader consensus on Polymarket prices a 0% implied probability for Hims & Hers Health (HIMS) to beat Q1 2026 earnings consensus of $0.04 per share and approximately $617 million in revenue, reflecting near-certain expectations of a miss driven by the company's February guidance of $600–625 million in sales—below initial Street estimates—due to a $65 million headwind from regulatory restrictions on compounded GLP-1 weight-loss drugs. Recent 23% downward revisions to EPS estimates over the past 30 days underscore margin pressures amid subscriber growth slowdowns in the core telehealth segment. Tail risks include upside surprises from cost efficiencies or higher-end revenue realization, though resolution after today's post-market release limits volatility windows.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题